Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologist;Miocardiopatía inducida por antraciclinas: Conocimientos moleculares básicos para el cardiólogo

Archivos de Cardiologia de Mexico

Volumn 84, Issue 3, 2014, Pages 218-223

  Salazar Mendiguchía, Joel ^a   González Costello, José ^a   Roca, Josep ^a   Ariza Solé, Albert ^a   Manito, Nicolás ^a   Cequier, Ángel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Anthracycline cardiotoxicity; Chemotherapy cardiomyopathy; Doxorubicin cardiomyopathy; Spain

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANKYRIN; ANTHRACYCLINE; DRUG METABOLITE; HISTAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR GATA 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; HUMAN; IRON METABOLISM; MACROPHAGE; MONOCYTE; OXIDATIVE STRESS; SARCOMERE; CARDIOLOGY; CHEMICALLY INDUCED; METABOLISM;

ANTHRACYCLINES; CARDIOLOGY; CARDIOMYOPATHIES; HUMANS;

EID: 84907616938     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acmx.2013.08.006     Document Type: Short Survey

References (41)

1. Arcamone F, Franceschi G, Penco S, et al. Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett. 1969;13:1007-10.
2. Menna P, González O, Chello M, et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11:S21-36.
3. Aebi S, Davidson T, Gruber G, et al. ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:9-14.
4. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187-205.
5. Gianni L, Herman E, Lipshultz SE, et al. Anthraycline cardiotoxicity from bench to bedside. J Clin Oncol. 2008;26:3777-84.
6. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-79.
7. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7:56-60.
8. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1-10.
9. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology: clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991-4008.
10. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544-52.
11. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163-72.
12. Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19:3173-81.
13. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2006;56:106-30.
14. Pai BP, Nahata M. Cardiotoxicity of chemotherapeutic agents, incidence, treatment and prevention. Drug Saf. 2000;22:263-302.
15. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56: 185-229.
16. L’Ecuyer T, Sanjeev S, Thomas R, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol. 2006;291:H370-8.
17. Octavia y, Tocchetti C, Gabrielson K, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-25.
18. Fu LX, Waagstein F, Hjalmarson A. A new insight intro adriamycin-induced cardiotoxicity. Int J Cardiol. 1990;29: 15-20.
19. Menna P, Salvatorelli E, Gianni L, et al. Anthracycline cardiotoxicity. Top Curr Chem. 2008;283:21-44.
20. Tandara L, Salamunic I. Iron metabolism: current facts and future directions. Biochem Med. 2012;22:311-28.
21. Minotti G, Ronchi R, Salvatorelli E, et al. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001;61:8422-8.
22. Simunek T, Sterba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of oxidative stress and free cellular iron. Pharm Rep. 2009;61:154-71.
23. Halliwell B, Gutteridge J. Free radicals in biology and medicine. Oxford, NY: Oxford University Press; 2007.
24. Brazzolotto X, Andriollo M, Guiraud P, et al. Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta. 2003;17:209-18.
25. Pantjrath GS, Patel V, Valdiviezo Cl Narula N, et al. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol. 2007;49:2457-64.
26. Cascales A, Sánchez-Vega B, Navarro N, et al. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int J Cardiol. 2012;154:282-6.
27. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol. 2004;555:1-13.
28. Praet M, Ruysschaert JM. In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives. Biochim Biophys Acta. 1993;1149:79-85.
29. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 2003;93:105-15.
30. Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41:389-405.
31. Gautel M. The sarcomeric cytoskeleton: who picks up the strain. Curr Opin Cell Biol. 2011;23:39-46.
32. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619-28.
33. McNally EM. Genetics: broken giant linked to heart failure. Nature. 2012;14:281-2.
34. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;27:8290-9.
35. Sawyer D, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardio-protection. Prog Cardiovasc Dis. 2010;53:105-13.
36. Chen B, Zhong L, Roush S, et al. Disruption of GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: implications for anthracycline cardiomyopathy. PLoS ONE. 2012;7:1-13.
37. Schubert C, Hong S, Natarajan L, et al. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun. 2007;21:413-27.
38. Wong J, Smith LB, Magun EA, et al. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther. 2013;14:56-63.
39. Chiosi E, Spina A, Sorrentino A, et al. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res. 2007;27:589-97.
40. Blanco JG, Leisenring WM, González-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-95.
41. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754-62.